Alpa Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: May 31, 2025, 9:40 pm

Market Cap	209 Cr.
Current Price	99.1
High / Low	145/69.9
Stock P/E	10.6
Book Value	86.4
Dividend Yield	0.00 %
ROCE	15.0 %
ROE	11.4 %
Face Value	10.0
PEG Ratio	0.37

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Alpa Laboratories Ltd

Competitors of Alpa Laboratories Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	134 Cr.	95.0	247/84.3	26.0	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.27 Cr.	2.76	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	39.9 Cr.	53.8	94.9/44.5		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	41.1 Cr.	28.0	29.1/13.1	40.3	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	18,354.98 Cr	1,129.60		88.53	194.54	0.32%	16.70%	15.22%	6.19

All Competitor Stocks of Alpa Laboratories Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	25.50	22.42	13.54	27.31	29.16	25.43	32.39	27.31	23.61	21.44	24.94	26.15	39.11
Expenses	26.86	21.00	19.28	24.68	19.90	26.58	29.07	24.85	20.10	20.90	21.67	25.41	39.47
Operating Profit	-1.36	1.42	-5.74	2.63	9.26	-1.15	3.32	2.46	3.51	0.54	3.27	0.74	-0.36
OPM %	-5.33%	6.33%	-42.39%	9.63%	31.76%	-4.52%	10.25%	9.01%	14.87%	2.52%	13.11%	2.83%	-0.92%
Other Income	3.72	1.61	6.38	2.69	-0.76	4.47	2.95	3.55	3.97	5.18	6.91	8.80	3.24
Interest	0.07	0.03	0.08	0.07	0.04	0.02	0.04	0.03	0.30	0.05	0.06	0.10	0.05
Depreciation	0.50	0.34	0.36	0.10	0.53	0.28	0.49	0.66	0.52	0.54	0.53	0.55	0.58
Profit before tax	1.79	2.66	0.20	5.15	7.93	3.02	5.74	5.32	6.66	5.13	9.59	8.89	2.25
Tax %	304.47%	0.00%	0.00%	0.00%	41.74%	0.00%	0.00%	14.85%	46.70%	0.00%	20.44%	0.00%	186.67%
Net Profit	-3.66	2.66	0.20	5.14	4.62	3.03	5.74	4.53	3.55	5.12	7.63	8.89	-1.95
EPS in Rs	-1.74	1.26	0.10	2.44	2.20	1.44	2.73	2.15	1.69	2.43	3.63	4.23	-0.93

Last Updated: May 31, 2025, 9:52 am

Below is a detailed analysis of the quarterly data for Alpa Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 39.11 Cr.. The value appears strong and on an upward trend. It has increased from 26.15 Cr. (Dec 2024) to 39.11 Cr., marking an increase of 12.96 Cr..
For Expenses, as of Mar 2025, the value is 39.47 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 25.41 Cr. (Dec 2024) to 39.47 Cr., marking an increase of 14.06 Cr..
For Operating Profit, as of Mar 2025, the value is -0.36 Cr.. The value appears to be declining and may need further review. It has decreased from 0.74 Cr. (Dec 2024) to -0.36 Cr., marking a decrease of 1.10 Cr..
For OPM %, as of Mar 2025, the value is -0.92%. The value appears to be declining and may need further review. It has decreased from 2.83% (Dec 2024) to -0.92%, marking a decrease of 3.75%.
For Other Income, as of Mar 2025, the value is 3.24 Cr.. The value appears to be declining and may need further review. It has decreased from 8.80 Cr. (Dec 2024) to 3.24 Cr., marking a decrease of 5.56 Cr..
For Interest, as of Mar 2025, the value is 0.05 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.10 Cr. (Dec 2024) to 0.05 Cr., marking a decrease of 0.05 Cr..
For Depreciation, as of Mar 2025, the value is 0.58 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.55 Cr. (Dec 2024) to 0.58 Cr., marking an increase of 0.03 Cr..
For Profit before tax, as of Mar 2025, the value is 2.25 Cr.. The value appears to be declining and may need further review. It has decreased from 8.89 Cr. (Dec 2024) to 2.25 Cr., marking a decrease of 6.64 Cr..
For Tax %, as of Mar 2025, the value is 186.67%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Dec 2024) to 186.67%, marking an increase of 186.67%.
For Net Profit, as of Mar 2025, the value is -1.95 Cr.. The value appears to be declining and may need further review. It has decreased from 8.89 Cr. (Dec 2024) to -1.95 Cr., marking a decrease of 10.84 Cr..
For EPS in Rs, as of Mar 2025, the value is -0.93. The value appears to be declining and may need further review. It has decreased from 4.23 (Dec 2024) to -0.93, marking a decrease of 5.16.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 7, 2025, 9:19 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	56	56	57	53	63	62	77	85	97	112	93	109	96
Expenses	53	51	54	47	56	57	76	79	90	101	85	100	88
Operating Profit	3	6	3	7	7	4	1	6	8	11	8	9	8
OPM %	5%	10%	6%	13%	11%	7%	2%	7%	8%	10%	9%	8%	8%
Other Income	0	1	2	6	4	5	5	0	4	11	9	14	25
Interest	2	2	2	1	2	1	1	0	0	0	0	0	1
Depreciation	5	9	6	1	1	1	1	1	1	2	1	2	2
Profit before tax	-3	-5	-3	11	9	7	5	5	11	20	16	21	30
Tax %	36%	4%	-48%	27%	34%	27%	36%	20%	33%	28%	21%	19%
Net Profit	-4	-5	-1	8	6	5	3	4	7	14	13	17	25
EPS in Rs	-2.08	-2.45	-0.67	3.68	2.85	2.27	1.40	1.94	3.45	6.72	6.00	7.98	11.98
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	-25.00%	80.00%	900.00%	-25.00%	-16.67%	-40.00%	33.33%	75.00%	100.00%	-7.14%	30.77%
Change in YoY Net Profit Growth (%)	0.00%	105.00%	820.00%	-925.00%	8.33%	-23.33%	73.33%	41.67%	25.00%	-107.14%	37.91%

Alpa Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	7%
5 Years:	6%
3 Years:	0%
TTM:	3%

Compounded Profit Growth
10 Years:	55%
5 Years:	30%
3 Years:	36%
TTM:	14%

Stock Price CAGR
10 Years:	24%
5 Years:	40%
3 Years:	15%
1 Year:	22%

Return on Equity
10 Years:	7%
5 Years:	9%
3 Years:	11%
Last Year:	11%

Last Updated: Unknown

Balance Sheet

Last Updated: April 13, 2025, 4:06 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	21	21	21	21	21	21	21	21	21	21	21	21	21
Reserves	72	67	66	73	77	82	85	89	96	111	124	141	154
Borrowings	17	23	29	24	11	6	2	0	0	6	3	5	3
Other Liabilities	14	15	13	27	20	17	21	21	33	28	30	25	32
Total Liabilities	125	127	128	145	129	127	129	131	150	165	178	192	210
Fixed Assets	80	73	5	5	5	6	6	6	7	9	7	11	11
CWIP	0	0	0	0	0	0	0	1	2	0	0	0	0
Investments	0	0	10	22	23	41	59	68	62	86	90	109	128
Other Assets	45	54	113	118	100	79	64	56	80	70	81	72	71
Total Assets	125	127	128	145	129	127	129	131	150	165	178	192	210

Below is a detailed analysis of the balance sheet data for Alpa Laboratories Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 21.00 Cr..
For Reserves, as of Sep 2024, the value is 154.00 Cr.. The value appears strong and on an upward trend. It has increased from 141.00 Cr. (Mar 2024) to 154.00 Cr., marking an increase of 13.00 Cr..
For Borrowings, as of Sep 2024, the value is 3.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 5.00 Cr. (Mar 2024) to 3.00 Cr., marking a decrease of 2.00 Cr..
For Other Liabilities, as of Sep 2024, the value is 32.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 25.00 Cr. (Mar 2024) to 32.00 Cr., marking an increase of 7.00 Cr..
For Total Liabilities, as of Sep 2024, the value is 210.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 192.00 Cr. (Mar 2024) to 210.00 Cr., marking an increase of 18.00 Cr..
For Fixed Assets, as of Sep 2024, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 11.00 Cr..
For CWIP, as of Sep 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Investments, as of Sep 2024, the value is 128.00 Cr.. The value appears strong and on an upward trend. It has increased from 109.00 Cr. (Mar 2024) to 128.00 Cr., marking an increase of 19.00 Cr..
For Other Assets, as of Sep 2024, the value is 71.00 Cr.. The value appears to be declining and may need further review. It has decreased from 72.00 Cr. (Mar 2024) to 71.00 Cr., marking a decrease of 1.00 Cr..
For Total Assets, as of Sep 2024, the value is 210.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Mar 2024) to 210.00 Cr., marking an increase of 18.00 Cr..

Notably, the Reserves (154.00 Cr.) exceed the Borrowings (3.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	8	-2	-25	-8	-7	-1	18	-1	2	10	4
Cash from Investing Activity +	-2	37	-7	1	-16	-15	-11	6	-16	1	-12
Cash from Financing Activity +	4	7	-6	-2	4	-5	-1	-0	5	-3	2
Net Cash Flow	10	42	-37	-9	-19	-20	5	4	-8	8	-6

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-14.00	-17.00	-26.00	-17.00	-4.00	-2.00	-1.00	6.00	8.00	5.00	5.00	4.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	127	130	156	234	169	151	141	105	133	124	186	138
Inventory Days	132	148	76	196	131	140	105	90	102	81	84	73
Days Payable	85	121	91	244	140	130	99	98	152	78	100	63
Cash Conversion Cycle	174	157	141	187	160	161	148	97	83	127	170	149
Working Capital Days	187	169	178	390	256	234	194	121	137	136	157	150
ROCE %	-1%	-3%	0%	10%	11%	7%	4%	7%	7%	9%	11%	14%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%
FIIs	0.56%	0.21%	0.14%	0.00%	0.00%	0.00%	0.11%	0.95%	0.50%	0.36%	0.74%	0.35%
DIIs	0.00%	0.00%	0.00%	0.00%	0.01%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	42.15%	42.50%	42.56%	42.70%	42.70%	42.70%	42.59%	41.74%	42.21%	42.35%	41.97%	42.34%
No. of Shareholders	18,775	18,796	18,840	19,094	19,137	18,745	18,565	18,682	18,690	18,116	18,885	19,206

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	8.01	5.88	6.70	3.44	0.88
Diluted EPS (Rs.)	8.01	5.88	6.70	3.44	0.89
Cash EPS (Rs.)	8.90	6.61	7.48	4.03	2.38
Book Value[Excl.RevalReserv]/Share (Rs.)	72.20	63.96	57.85	51.16	47.70
Book Value[Incl.RevalReserv]/Share (Rs.)	72.20	63.96	57.85	51.16	47.70
Revenue From Operations / Share (Rs.)	51.68	44.18	53.36	46.36	40.86
PBDIT / Share (Rs.)	10.93	8.29	10.19	5.75	2.98
PBIT / Share (Rs.)	10.00	7.66	9.40	5.16	1.48
PBT / Share (Rs.)	9.83	7.55	9.30	5.13	1.38
Net Profit / Share (Rs.)	7.97	5.98	6.70	3.44	0.88
NP After MI And SOA / Share (Rs.)	7.97	5.98	6.70	3.44	0.88
PBDIT Margin (%)	21.14	18.76	19.09	12.39	7.29
PBIT Margin (%)	19.35	17.33	17.61	11.13	3.61
PBT Margin (%)	19.01	17.09	17.42	11.05	3.38
Net Profit Margin (%)	15.42	13.53	12.55	7.42	2.15
NP After MI And SOA Margin (%)	15.42	13.53	12.55	7.42	2.15
Return on Networth / Equity (%)	11.04	9.34	11.57	6.73	1.84
Return on Capital Employeed (%)	13.63	11.90	15.97	10.07	3.08
Return On Assets (%)	9.19	7.52	9.07	5.16	1.52
Long Term Debt / Equity (X)	0.00	0.01	0.01	0.00	0.00
Total Debt / Equity (X)	0.03	0.01	0.04	0.00	0.00
Asset Turnover Ratio (%)	0.62	0.57	0.73	0.71	0.68
Current Ratio (X)	5.74	4.67	4.43	3.73	4.59
Quick Ratio (X)	5.25	4.28	3.93	3.22	3.99
Inventory Turnover Ratio (X)	4.78	3.73	3.96	3.73	3.72
Interest Coverage Ratio (X)	64.02	78.01	97.84	155.24	31.95
Interest Coverage Ratio (Post Tax) (X)	47.71	57.27	65.32	94.03	10.45
Enterprise Value (Cr.)	179.04	106.65	149.57	65.56	23.69
EV / Net Operating Revenue (X)	1.65	1.15	1.33	0.67	0.27
EV / EBITDA (X)	7.79	6.11	6.98	5.42	3.78
MarketCap / Net Operating Revenue (X)	1.61	1.22	1.30	0.77	0.34
Price / BV (X)	1.16	0.84	1.20	0.70	0.29
Price / Net Operating Revenue (X)	1.61	1.22	1.30	0.77	0.34
EarningsYield	0.09	0.11	0.09	0.09	0.06

After reviewing the key financial ratios for Alpa Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 8.01. This value is within the healthy range. It has increased from 5.88 (Mar 23) to 8.01, marking an increase of 2.13.
For Diluted EPS (Rs.), as of Mar 24, the value is 8.01. This value is within the healthy range. It has increased from 5.88 (Mar 23) to 8.01, marking an increase of 2.13.
For Cash EPS (Rs.), as of Mar 24, the value is 8.90. This value is within the healthy range. It has increased from 6.61 (Mar 23) to 8.90, marking an increase of 2.29.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 72.20. It has increased from 63.96 (Mar 23) to 72.20, marking an increase of 8.24.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 72.20. It has increased from 63.96 (Mar 23) to 72.20, marking an increase of 8.24.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 51.68. It has increased from 44.18 (Mar 23) to 51.68, marking an increase of 7.50.
For PBDIT / Share (Rs.), as of Mar 24, the value is 10.93. This value is within the healthy range. It has increased from 8.29 (Mar 23) to 10.93, marking an increase of 2.64.
For PBIT / Share (Rs.), as of Mar 24, the value is 10.00. This value is within the healthy range. It has increased from 7.66 (Mar 23) to 10.00, marking an increase of 2.34.
For PBT / Share (Rs.), as of Mar 24, the value is 9.83. This value is within the healthy range. It has increased from 7.55 (Mar 23) to 9.83, marking an increase of 2.28.
For Net Profit / Share (Rs.), as of Mar 24, the value is 7.97. This value is within the healthy range. It has increased from 5.98 (Mar 23) to 7.97, marking an increase of 1.99.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 7.97. This value is within the healthy range. It has increased from 5.98 (Mar 23) to 7.97, marking an increase of 1.99.
For PBDIT Margin (%), as of Mar 24, the value is 21.14. This value is within the healthy range. It has increased from 18.76 (Mar 23) to 21.14, marking an increase of 2.38.
For PBIT Margin (%), as of Mar 24, the value is 19.35. This value is within the healthy range. It has increased from 17.33 (Mar 23) to 19.35, marking an increase of 2.02.
For PBT Margin (%), as of Mar 24, the value is 19.01. This value is within the healthy range. It has increased from 17.09 (Mar 23) to 19.01, marking an increase of 1.92.
For Net Profit Margin (%), as of Mar 24, the value is 15.42. This value exceeds the healthy maximum of 10. It has increased from 13.53 (Mar 23) to 15.42, marking an increase of 1.89.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 15.42. This value is within the healthy range. It has increased from 13.53 (Mar 23) to 15.42, marking an increase of 1.89.
For Return on Networth / Equity (%), as of Mar 24, the value is 11.04. This value is below the healthy minimum of 15. It has increased from 9.34 (Mar 23) to 11.04, marking an increase of 1.70.
For Return on Capital Employeed (%), as of Mar 24, the value is 13.63. This value is within the healthy range. It has increased from 11.90 (Mar 23) to 13.63, marking an increase of 1.73.
For Return On Assets (%), as of Mar 24, the value is 9.19. This value is within the healthy range. It has increased from 7.52 (Mar 23) to 9.19, marking an increase of 1.67.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.01 (Mar 23) to 0.00, marking a decrease of 0.01.
For Total Debt / Equity (X), as of Mar 24, the value is 0.03. This value is within the healthy range. It has increased from 0.01 (Mar 23) to 0.03, marking an increase of 0.02.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.62. It has increased from 0.57 (Mar 23) to 0.62, marking an increase of 0.05.
For Current Ratio (X), as of Mar 24, the value is 5.74. This value exceeds the healthy maximum of 3. It has increased from 4.67 (Mar 23) to 5.74, marking an increase of 1.07.
For Quick Ratio (X), as of Mar 24, the value is 5.25. This value exceeds the healthy maximum of 2. It has increased from 4.28 (Mar 23) to 5.25, marking an increase of 0.97.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 4.78. This value is within the healthy range. It has increased from 3.73 (Mar 23) to 4.78, marking an increase of 1.05.
For Interest Coverage Ratio (X), as of Mar 24, the value is 64.02. This value is within the healthy range. It has decreased from 78.01 (Mar 23) to 64.02, marking a decrease of 13.99.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 47.71. This value is within the healthy range. It has decreased from 57.27 (Mar 23) to 47.71, marking a decrease of 9.56.
For Enterprise Value (Cr.), as of Mar 24, the value is 179.04. It has increased from 106.65 (Mar 23) to 179.04, marking an increase of 72.39.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.65. This value is within the healthy range. It has increased from 1.15 (Mar 23) to 1.65, marking an increase of 0.50.
For EV / EBITDA (X), as of Mar 24, the value is 7.79. This value is within the healthy range. It has increased from 6.11 (Mar 23) to 7.79, marking an increase of 1.68.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.61. This value is within the healthy range. It has increased from 1.22 (Mar 23) to 1.61, marking an increase of 0.39.
For Price / BV (X), as of Mar 24, the value is 1.16. This value is within the healthy range. It has increased from 0.84 (Mar 23) to 1.16, marking an increase of 0.32.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.61. This value is within the healthy range. It has increased from 1.22 (Mar 23) to 1.61, marking an increase of 0.39.
For EarningsYield, as of Mar 24, the value is 0.09. This value is below the healthy minimum of 5. It has decreased from 0.11 (Mar 23) to 0.09, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Alpa Laboratories Ltd as of June 1, 2025 is: 85.20

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 1, 2025, Alpa Laboratories Ltd is Overvalued by 14.03% compared to the current share price 99.10

Intrinsic Value of Alpa Laboratories Ltd as of June 1, 2025 is: 109.29

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 1, 2025, Alpa Laboratories Ltd is Undervalued by 10.28% compared to the current share price 99.10

Last 5 Year EPS CAGR: 28.27%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (95.15 cr) compared to borrowings (9.92 cr), indicating strong financial stability. The company has shown consistent growth in sales (78.15 cr) and profit (9.54 cr) over the years.	The stock has a low average ROCE of 6.33%, which may not be favorable. The stock has a high average Working Capital Days of 192.42, which may not be favorable. The stock has a high average Cash Conversion Cycle of 146.17, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alpa Laboratories Ltd:
1. Net Profit Margin: 15.42%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 13.63% (Industry Average ROCE: 16.56%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 11.04% (Industry Average ROE: 14.72%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 47.71
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 5.25
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 10.6 (Industry average Stock P/E: 74.01)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.03
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Alpa Laboratories Ltd. is a Public Limited Listed company incorporated on 18/03/1988 and has its registered office in the State of Madhya Pradesh, India. Company's Corporate Identification Number(CIN) is L85195MP1988PLC004446 and registration number is 004446. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 108.74 Cr. and Equity Capital is Rs. 21.04 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	33/2, Pigdamber, A.B.Road, Rau, Indore Madhya Pradesh 453446	is@alpalabs.in http://www.alpalabs.in

Management
Name	Position Held
Mr. Mahendra Singh Chawla	Chairman
Mr. Paresh Chawla	Managing Director
Mrs. Jyoti Jain	Independent Director
Mr. Pravin Shah	Director
Mr. Vitthal Kothana	Director
Mr. Sanket Baheti	Independent Director
Mr. Shitul Shah	Director
Mr. Sunil Kumar Valecha	Independent Director
Mrs. Pratibha Lunawat	Independent Director

FAQ

What is the intrinsic value of Alpa Laboratories Ltd?

Alpa Laboratories Ltd's intrinsic value (as of 01 June 2025) is ₹85.20 — 14.03% lower the current market price of 99.10, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 209 Cr. market cap, FY2025-2026 high/low of ₹145/69.9, reserves of 154 Cr, and liabilities of 210 Cr.

What is the Market Cap of Alpa Laboratories Ltd?

The Market Cap of Alpa Laboratories Ltd is 209 Cr..

What is the current Stock Price of Alpa Laboratories Ltd as on 01 June 2025?

The current stock price of Alpa Laboratories Ltd as on 01 June 2025 is 99.1.

What is the High / Low of Alpa Laboratories Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Alpa Laboratories Ltd stocks is ₹145/69.9.

What is the Stock P/E of Alpa Laboratories Ltd?

The Stock P/E of Alpa Laboratories Ltd is 10.6.

What is the Book Value of Alpa Laboratories Ltd?

The Book Value of Alpa Laboratories Ltd is 86.4.

What is the Dividend Yield of Alpa Laboratories Ltd?

The Dividend Yield of Alpa Laboratories Ltd is 0.00 %.

What is the ROCE of Alpa Laboratories Ltd?

The ROCE of Alpa Laboratories Ltd is 15.0 %.

What is the ROE of Alpa Laboratories Ltd?

The ROE of Alpa Laboratories Ltd is 11.4 %.

What is the Face Value of Alpa Laboratories Ltd?

The Face Value of Alpa Laboratories Ltd is 10.0.